RedHill Biopharma (NASDAQ:RDHL) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Price Performance

RDHL stock opened at $6.44 on Friday. The company’s 50-day moving average price is $6.79 and its 200 day moving average price is $56.06. RedHill Biopharma has a 52 week low of $5.41 and a 52 week high of $20.27.

Hedge Funds Weigh In On RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC bought a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.